Literature DB >> 9298384

Symptomatic giant cavernous haemangioma of the liver: is enucleation a safe method? A single institution report.

H Demiryürek1, O Alabaz, D Ağdemir, I Sungur, E U Erkoçak, A Akinoğlu, A Alparslan, S Zorludemir.   

Abstract

Twenty-three patients with symptomatic giant hemangioma of the liver were treated by surgery between 1979 and 1996 at the department of General Surgery, Faculty of Medicine, University of Cukurova. Twenty-three enucleations were performed in 21 patients, left lateral segmentectomy in one patient and enucleation plus left lobectomy in one patient. The tumors were enucleated along the interface between the hemangioma and normal liver tissue. The diameters of the tumors ranged from 5 x 5 to 25 x 15 cm. The mean blood loss for enucleations was 525 ml (range 500-1000 ml). There was no mortality and no postoperative bleeding. Three patients had postoperative complications. Enucleation is the best surgical technique for symptomatic giant hemangioma of the liver. It may be performed with no mortality, low morbidity and the preservation of all normal liver parenchyma.

Entities:  

Mesh:

Year:  1997        PMID: 9298384      PMCID: PMC2423897          DOI: 10.1155/1997/53453

Source DB:  PubMed          Journal:  HPB Surg        ISSN: 0894-8569


  3 in total

1.  Enucleation versus Anatomic Resection for Giant Hepatic Hemangioma: A Meta-Analysis.

Authors:  Yuhui Liu; Xuyong Wei; Kun Wang; Qiaonan Shan; Haojiang Dai; Haiyang Xie; Lin Zhou; Xiao Xu; Shusen Zheng
Journal:  Gastrointest Tumors       Date:  2017-02-11

2.  Surgical treatment of giant liver hemangiomas: enucleation with continuous occlusion of hepatic artery proper and intermittent Pringle maneuver.

Authors:  Feng Xia; Wan-Yee Lau; Cheng Qian; Shuguang Wang; Kuansheng Ma; Ping Bie
Journal:  World J Surg       Date:  2010-09       Impact factor: 3.352

3.  Giant haemangioma of the liver: is enucleation better than resection?

Authors:  Rajneesh Kumar Singh; Sorabh Kapoor; Peush Sahni; Tushar K Chattopadhyay
Journal:  Ann R Coll Surg Engl       Date:  2007-07       Impact factor: 1.891

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.